阿扎那韦（CAS 198904-31-3）：分子式 C38H52N6O7、分子量 704.9。
| CAS号 | 198904-31-3 |
|---|---|
| 分子式 | C38H52N6O7 |
| 分子量 | 704.9 |
| LogP | 4.5 |
| 应用领域 | Uses: Human immunodeficiency virus (HIV) infection (treatment). Atazanavir sulfate is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.、Atazanavir Sulfate、Medication、Use (kg、approx.) in Germany (2009): >500、Consumption (g per capita、approx.) in Germany (2009): 0.00611、Excretion rate: 0.3、Calculated removal (%): 4.8、Formulations、Preparations: Oral: Capsules: 100 mg (of atazanavir) Reyataz、(Bristol-Myers Squibb)、150 mg (of atazanavir) Reyataz、200 mg (of atazanavir) Reyataz、(Bristol-Myers Squibb).、General Manufacturing Information: While data specific to atazanavir were not available(SRC、2005)、the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Studies have indicated that several polar pharmaceutically active compounds can leach through subsoils into aquifers(1). |
登记用途：Uses: Human immunodeficiency virus (HIV) infection (treatment). Atazanavir sulfate is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.、Atazanavir Sulfate、Medication、Use (kg、approx.) in Germany (2009): >500、Consumption (g per capita、approx.) in Germany (2009): 0.00611、Excretion rate: 0.3、Calculated removal (%): 4.8、Formulations、Preparations: Oral: Capsules: 100 mg (of atazanavir) Reyataz、(Bristol-Myers Squibb)、150 mg (of atazanavir) Reyataz、200 mg (of atazanavir) Reyataz、(Bristol-Myers Squibb).、General Manufacturing Information: While data specific to atazanavir were not available(SRC、2005)、the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Studies have indicated that several polar pharmaceutically active compounds can leach through subsoils into aquifers(1).。
阿扎那韦 是一种化工化合物，登记 CAS 号为 198904-31-3，分子式 C38H52N6O7（分子量 704.9）。
登记 CAS 号：198904-31-3
其分子式 C38H52N6O7 由 38 个碳、52 个氢、6 个氮、7 个氧 组成。
别名/同义词：阿扎那韦 · Atazanavir
阿扎那韦 的 CAS 登记号为 198904-31-3。
分子式 C38H52N6O7，分子量 704.9。
别名/同义词：阿扎那韦、Atazanavir。
登记用途：Uses: Human immunodeficiency virus (HIV) infection (treatment). Atazanavir sulfate is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.、Atazanavir Sulfate、Medication、Use (kg、approx.) in Germany (2009): >500、Consumption (g per capita、approx.) in Germany (2009): 0.00611、Excretion rate: 0.3、Calculated removal (%): 4.8、Formulations、Preparations: Oral: Capsules: 100 mg (of atazanavir) Reyataz、(Bristol-Myers Squibb)、150 mg (of atazanavir) Reyataz、200 mg (of atazanavir) Reyataz、(Bristol-Myers Squibb).、General Manufacturing Information: While data specific to atazanavir were not available(SRC、2005)、the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Studies have indicated that several polar pharmaceutically active compounds can leach through subsoils into aquifers(1).。
阿扎那韦（CAS 198904-31-3）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 198904-31-3 |
|---|---|
| PubChem CID | 148192 |
| Molecular formula | C38H52N6O7 |
| IUPAC name | methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate |
| UNII (FDA) | QZU4H47A3S |
| Molecular Weight | 704.9 |
|---|---|
| XLogP3 | 5.6 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 18 |
| Exact Mass | 704.38974802 |
| Monoisotopic Mass | 704.38974802 |
| Topological Polar Surface Area | 171 |
| Heavy Atom Count | 51 |
| Solubility | 3.27e-03 g/L |
|---|---|
| LogP | 4.5 |
Atazanavir; 198904-31-3; Latazanavir; Zrivada; BMS-232632; atazanavirum; DTXSID9048691; QZU4H47A3S; CHEBI:37924; DTXCID5028617; RefChem:54330; J05AE08; CGP 73547; CGP-73547; BMS 232632; Atazanavir Base
| Reported hazard statements | H318 (66.7%), H319 (33.3%), H372 (66.7%), H411 (66.7%) |
|---|
H318 (66.7%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
H319 (33.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
Atazanavir · CAS 198904-31-3 · C38H52N6O7. UNII QZU4H47A3S. Solubility: 3.27e-03 g/L; LogP: 4.5.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Atazanavir